Full-Time

Associate Director Chemical Development

Updated on 3/15/2025

Acadia Pharmaceuticals

Acadia Pharmaceuticals

501-1,000 employees

Develops therapies for neurological disorders

No salary listed

Senior

Princeton, NJ, USA

Hybrid model requires this role to work in the office three days per week on average.

Category
Lab & Research
Life Sciences
Medical Research
Requirements
  • PhD in synthetic organic chemistry or a related field
  • Targeting 8 years of experience in pharmaceutical research, development and manufacturing
  • 2 years’ experience in a leadership role preferably in process development, process characterization, process validation, drug substance manufacturing and/or product life cycle management
  • Leadership experience in managing diverse project activities with contract CDMO facilities at different global locations
  • Experience with global pharmaceutical/chemical development and manufacturing operations for development-stage small molecules
  • Highly knowledgeable with FDA and ICH guidelines relating to registration, quality and compliance with small molecule drug substance
  • Strong understanding of organic synthetic chemistry concepts and cross-functional understanding related to API development and manufacturing from pre-IND through NDA
  • Chemistry Manufacturing Controls (CMC) expertise to prepare documents for regulatory filing (e.g. IND to NDA)
  • Extensive knowledge of current Good Manufacturing Practices (cGMPs)
  • Excellent communication, interpersonal and presentation skills
  • Ability to effectively collaborate with and direct the work of others on assigned projects
  • Skilled at negotiating with business partners/management and influencing senior level leaders regarding matters of significance to the organization
  • Demonstrated problem-solving abilities and conflict resolution skills
  • Proficient at creating and communicating a clear vision among team members effectively aligning resources and activities to achieve functional area and/or organizational goals
Responsibilities
  • Provide strong scientific support to the overall chemical development team
  • Oversee contract development organizations to lead the development and optimization of drug substance processes
  • Perform risk assessments of manufacturing process scale-up and use Quality by Design (QbD) principles
  • Formulate drug substance development strategy to ensure product quality
  • Facilitate technology transfer, chemical outsourcing, external manufacturing
  • Foster an inclusive workplace, creating staff development opportunities
  • Engage in all facets of development from small scale synthesis to the development of the commercial synthetic route
  • Develop and implement strategic and operational plans to deliver drug substance for multiple development projects
  • Initiate, evaluate and validate new drug substance CSPs (Contract Service Providers)
  • Establish and maintain good working relationships with contract service providers
  • Work with CSPs to diagnose and correct process issues
  • Work with Quality function to determine the impact of process deviations
  • Develop timelines, goals, and deliverables for drug substances
  • Optimize the manufacturing process to maintain high product quality
  • Ensure the supply of drug substance is consistent with development plans
  • Ensure CSPs remain current and compliant with all cGMP related requirements
  • Track deviations and processes changes for the different suppliers
  • Initiate and coordinate the preparation of CMC documentation
  • Collaborate with Regulatory Affairs and other groups to support product filings
  • Assist in contract site preparation activities for pre-approval inspections
  • Support interdisciplinary working teams with recommendations, advice and action plans
  • Evaluate new process technology ensuring freedom to operate
  • Provide onsite process coverage during process validation
  • Communicate drug substance related issues and information to committees, teams and interested groups
  • Support corporate development activities, serving as drug substance/chemistry expert
Acadia Pharmaceuticals

Acadia Pharmaceuticals

View

Acadia Pharmaceuticals develops therapies for neurological disorders, focusing on conditions like Parkinson's disease, schizophrenia, and Rett syndrome. The company conducts extensive research and clinical trials to create drugs that are safe and effective, seeking approval from regulatory bodies like the FDA before bringing them to market. Acadia differentiates itself by targeting areas with significant unmet medical needs, ensuring that their products address critical health challenges. Their goal is to improve the quality of life for patients suffering from these conditions while also promoting diversity and inclusion within their operations.

Company Size

501-1,000

Company Stage

IPO

Headquarters

San Diego, California

Founded

1993

Simplify Jobs

Simplify's Take

What believers are saying

  • Acadia's DAYBUE is now available for treating Rett syndrome in the U.S.
  • The partnership with Neuren Pharmaceuticals strengthens Acadia's position in the rare disease market.
  • Increased focus on personalized medicine benefits Acadia's tailored CNS disorder therapies.

What critics are saying

  • A class action lawsuit could lead to financial liabilities and reputational damage.
  • Increased competition in CNS treatments may impact Acadia's market share.
  • Reliance on partnerships poses risks if collaborations face challenges or fail.

What makes Acadia Pharmaceuticals unique

  • Acadia focuses on CNS disorders with a strong pipeline of small molecule drugs.
  • The company has a unique partnership with Stoke Therapeutics for RNA-based therapies.
  • Acadia's documentary series raises awareness for Rett syndrome, enhancing its community engagement.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Employee Stock Purchase Plan

Paid Vacation

Paid Holidays

Paid Sick Leave

Paid Parental Leave

Tuition Reimbursement

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

2%

2 year growth

2%
Fierce Pharma
Dec 9th, 2024
Acadia nabs Lexicon, Bristol Myers Squibb veteran as new commercial lead

Acadia Pharmaceuticals has hired Big Pharma veteran Thomas Andrew Garner as its new chief commercial officer (CCO).

MarketWatch
Nov 26th, 2024
Acadia Pharmaceuticals in Exclusive License Agreement With Saniona for SAN711

Acadia Pharmaceuticals on Tuesday said it entered into an exclusive worldwide license agreement with Saniona to develop and commercialize SAN711.

World Pharmaceuticals
Oct 17th, 2024
Acadia gets Health Canada approval for Daybue to treat Rett Syndrome

US-based biopharmaceutical company Acadia Pharmaceuticals has received Health Canada marketing authorisation for Daybue (trofinetide) to treat a rare genetic neurological disorder.

PRWeb
Aug 23rd, 2024
Global Genes' Annual Week In Rare Event Heading To Kansas City

"Week in RARE provides advocates a unique opportunity to participate in multiple events in one place to maximize their time, travel, and potential to gain benefits from their participation."

Yahoo Finance
Aug 15th, 2024
Ryan Reynolds Announces More To Parkinson'S(R) Campaign

Ryan & Tammy Reynolds (Photo: Business Wire)Acadia Parkinson's Fact Sheet-- The national disease awareness campaign aims to educate and drive conversation about recognizing and managing non-motor symptoms of Parkinson’s, including hallucinations and delusions-- Reynolds and his mother Tammy share their personal story about the impact of these symptoms on their familySAN DIEGO, August 14, 2024--(BUSINESS WIRE)--Ryan Reynolds, a world-renowned actor/entrepreneur and Parkinson’s disease advocate, with Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the launch of a multi-faceted disease education campaign, More to Parkinson’s®, to raise awareness among caregivers, patients and their care providers about a common, yet under-recognized aspect of Parkinson’s disease – Parkinson’s-related hallucinations and delusions.Notably, around half of the people living with Parkinson’s disease may develop hallucinations or delusions over the course of their disease, but up to 90% of people currently do not proactively tell their physicians about these symptoms.1-3 By sharing their experiences caring for Ryan’s father, James "Jim" Reynolds, who passed away nearly a decade ago, Ryan and his mother Tammy, aim to raise awareness, educate and drive conversation between people with Parkinson’s disease, their families and their doctors about how best to talk about and treat these non-motor symptoms."My father experienced hallucinations and delusions. At the time, we didn’t know any of these types of symptoms were part of his Parkinson’s disease," Reynolds explains. "Like a lot of caregivers, my mom mostly tried to carry these burdens alone. I wish I’d known Parkinson’s disease wasn’t limited to only motor symptoms. I think people and families affected by Parkinson’s can be better prepared to manage hallucinations and delusions if they’re talking early and often about this lesser-known aspect of the disease."This press release features multimedia